Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders

Yu Chang Chen, Jui Sheng Wu, Hsin Da Tsai, Chien Yu Huang, Jin Jer Chen, Grace Y. Sun, Teng Nan Lin

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

As the growth of the aging population continues to accelerate globally, increased prevalence of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and stroke, has generated substantial public concern. Unfortunately, despite of discoveries of common factors underlying these diseases, few drugs are available to effectively treat these diseases. Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a ligand-activated transcriptional factor that belongs to the nuclear hormone receptor superfamily. PPAR-γ has been shown to influence the expression or activity of a large number of genes in a variety of signaling networks, including regulation of insulin sensitivity, glucose homeostasis, fatty acid oxidation, immune responses, redox balance, cardiovascular integrity, and cell fates. Recent epidemiological, preclinical animal, and clinical studies also show that PPAR- γ agonists can lower the incidence of a number of neurological disorders, despite of multiple etiological factors involved in the development of these disorders. In this manuscript, we review current knowledge on mechanisms underlying the beneficial effect of PPAR-γ in different neurodegenerative diseases, in particular, AD, PD, and stroke, and attempt to analyze common and overlapping features among these diseases. Our investigation unveiled information suggesting the ability for PPAR-γ to inhibit NF-κB-mediated inflammatory signaling at multiple sites, and conclude that PPAR-γ agonists represent a novel class of drugs for treating neuroinflammatory diseases.

Original languageEnglish
Pages (from-to)114-124
Number of pages11
JournalMolecular Neurobiology
Volume46
Issue number1
DOIs
Publication statusPublished - Jan 1 2012
Externally publishedYes

Fingerprint

Peroxisome Proliferator-Activated Receptors
PPAR gamma
Neurodegenerative Diseases
Parkinson Disease
Alzheimer Disease
Stroke
Aptitude
Population Growth
Cytoplasmic and Nuclear Receptors
Nervous System Diseases
Pharmaceutical Preparations
Oxidation-Reduction
Insulin Resistance
Homeostasis
Fatty Acids
Ligands
Glucose
Incidence
Genes

Keywords

  • Alzheimer's disease
  • Inflammation
  • Parkinson's disease
  • Stroke
  • Transcription factor

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders. / Chen, Yu Chang; Wu, Jui Sheng; Tsai, Hsin Da; Huang, Chien Yu; Chen, Jin Jer; Sun, Grace Y.; Lin, Teng Nan.

In: Molecular Neurobiology, Vol. 46, No. 1, 01.01.2012, p. 114-124.

Research output: Contribution to journalArticle

Chen, Yu Chang ; Wu, Jui Sheng ; Tsai, Hsin Da ; Huang, Chien Yu ; Chen, Jin Jer ; Sun, Grace Y. ; Lin, Teng Nan. / Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders. In: Molecular Neurobiology. 2012 ; Vol. 46, No. 1. pp. 114-124.
@article{4e90050d80eb447d9aa781630f6f8db0,
title = "Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders",
abstract = "As the growth of the aging population continues to accelerate globally, increased prevalence of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and stroke, has generated substantial public concern. Unfortunately, despite of discoveries of common factors underlying these diseases, few drugs are available to effectively treat these diseases. Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a ligand-activated transcriptional factor that belongs to the nuclear hormone receptor superfamily. PPAR-γ has been shown to influence the expression or activity of a large number of genes in a variety of signaling networks, including regulation of insulin sensitivity, glucose homeostasis, fatty acid oxidation, immune responses, redox balance, cardiovascular integrity, and cell fates. Recent epidemiological, preclinical animal, and clinical studies also show that PPAR- γ agonists can lower the incidence of a number of neurological disorders, despite of multiple etiological factors involved in the development of these disorders. In this manuscript, we review current knowledge on mechanisms underlying the beneficial effect of PPAR-γ in different neurodegenerative diseases, in particular, AD, PD, and stroke, and attempt to analyze common and overlapping features among these diseases. Our investigation unveiled information suggesting the ability for PPAR-γ to inhibit NF-κB-mediated inflammatory signaling at multiple sites, and conclude that PPAR-γ agonists represent a novel class of drugs for treating neuroinflammatory diseases.",
keywords = "Alzheimer's disease, Inflammation, Parkinson's disease, Stroke, Transcription factor",
author = "Chen, {Yu Chang} and Wu, {Jui Sheng} and Tsai, {Hsin Da} and Huang, {Chien Yu} and Chen, {Jin Jer} and Sun, {Grace Y.} and Lin, {Teng Nan}",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/s12035-012-8259-8",
language = "English",
volume = "46",
pages = "114--124",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders

AU - Chen, Yu Chang

AU - Wu, Jui Sheng

AU - Tsai, Hsin Da

AU - Huang, Chien Yu

AU - Chen, Jin Jer

AU - Sun, Grace Y.

AU - Lin, Teng Nan

PY - 2012/1/1

Y1 - 2012/1/1

N2 - As the growth of the aging population continues to accelerate globally, increased prevalence of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and stroke, has generated substantial public concern. Unfortunately, despite of discoveries of common factors underlying these diseases, few drugs are available to effectively treat these diseases. Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a ligand-activated transcriptional factor that belongs to the nuclear hormone receptor superfamily. PPAR-γ has been shown to influence the expression or activity of a large number of genes in a variety of signaling networks, including regulation of insulin sensitivity, glucose homeostasis, fatty acid oxidation, immune responses, redox balance, cardiovascular integrity, and cell fates. Recent epidemiological, preclinical animal, and clinical studies also show that PPAR- γ agonists can lower the incidence of a number of neurological disorders, despite of multiple etiological factors involved in the development of these disorders. In this manuscript, we review current knowledge on mechanisms underlying the beneficial effect of PPAR-γ in different neurodegenerative diseases, in particular, AD, PD, and stroke, and attempt to analyze common and overlapping features among these diseases. Our investigation unveiled information suggesting the ability for PPAR-γ to inhibit NF-κB-mediated inflammatory signaling at multiple sites, and conclude that PPAR-γ agonists represent a novel class of drugs for treating neuroinflammatory diseases.

AB - As the growth of the aging population continues to accelerate globally, increased prevalence of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and stroke, has generated substantial public concern. Unfortunately, despite of discoveries of common factors underlying these diseases, few drugs are available to effectively treat these diseases. Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a ligand-activated transcriptional factor that belongs to the nuclear hormone receptor superfamily. PPAR-γ has been shown to influence the expression or activity of a large number of genes in a variety of signaling networks, including regulation of insulin sensitivity, glucose homeostasis, fatty acid oxidation, immune responses, redox balance, cardiovascular integrity, and cell fates. Recent epidemiological, preclinical animal, and clinical studies also show that PPAR- γ agonists can lower the incidence of a number of neurological disorders, despite of multiple etiological factors involved in the development of these disorders. In this manuscript, we review current knowledge on mechanisms underlying the beneficial effect of PPAR-γ in different neurodegenerative diseases, in particular, AD, PD, and stroke, and attempt to analyze common and overlapping features among these diseases. Our investigation unveiled information suggesting the ability for PPAR-γ to inhibit NF-κB-mediated inflammatory signaling at multiple sites, and conclude that PPAR-γ agonists represent a novel class of drugs for treating neuroinflammatory diseases.

KW - Alzheimer's disease

KW - Inflammation

KW - Parkinson's disease

KW - Stroke

KW - Transcription factor

UR - http://www.scopus.com/inward/record.url?scp=84868121739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868121739&partnerID=8YFLogxK

U2 - 10.1007/s12035-012-8259-8

DO - 10.1007/s12035-012-8259-8

M3 - Article

VL - 46

SP - 114

EP - 124

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

IS - 1

ER -